New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies

Cryoport, Inc. is excited to announce a new strategic partnership with Syneos Health, a fully integrated biopharmaceutical solutions organization. Both organizations have deep expertise and experience supporting cell and gene therapies in both clinical and commercial stages. The new partnership will utilize the full suite of clinical development services offered by Syneos Health with IntegriCell™, Cryoport’s platform providing standardized apheresis collection, cryopreservation, storage and distribution.

Michael Brooks, COO of Syneos Health, explains that “this partnership will further help to accelerate treatment timelines and improve outcomes by expanding patient access to these life-changing therapies worldwide.”

Read the full announcement on Contract Pharma.